Menu
Not yet recruiting NCT07419022

Improv Music Therapy for Older Adults

No phase Interventional Alzheimer's Disease (AD) Older Adults (65 Years and Older)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Clinical Improvisation.
Who it may be relevant to
Registry conditions: Alzheimer's Disease (AD), Older Adults (65 Years and Older). Basic parameters: from 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Impact of Improvisation Music Therapy for Persons Living With Dementia and Their Care Partners

Overview

Older adults and their care partners will participate in music therapy sessions for approximately 8 weeks. Before and after the 8 week study period, participants will fill out questionnaires about their mood, stress levels, and emotions. During the music therapy sessions, they may be observed or asked questions about the music therapy sessions.

Interventions

  • Behavioral Clinical Improvisation
    Clinical improvisation music therapy offered as group sessions delivered by board-certified music therapist.

Primary outcome measures

  • Science of Behavior Change (SOBC) Brief-COPE [Time frame: Baseline and Post-Intervention, 8 weeks]
  • SOBC Perceived Stress Scale [Time frame: Baseline and Post Intervention, 8 weeks]
Secondary outcome measures (4)
  • Dementia Mood Picture Test [Time frame: Baseline and Post Intervention, 8 weeks]
  • SOBC Positive and Negative Affect (PANAS) [Time frame: Baseline and Post Intervention, 8 weeks]
  • Neuropsychiatric Inventory (NPI-Q) [Time frame: Baseline and Post Intervention, 8 weeks]
  • Kingston Caregivers STress Scale [Time frame: Baseline and Post-Intervention, 8 weeks]

Eligibility criteria

Inclusion criteria

Inclusion criteria for the Person Living with Dementia (PLWD) are:

  • Age 60 and over, living independently in the community
  • Medical diagnosis of Alzheimer's Disease
  • Mild dementia defined as MoCA score between 16-20, or MMSE score between 19-24
  • Sufficient visual and hearing acuity (age-related to normal hearing loss with assistive devices)
  • English fluency rated fairly well to well (self-rated English fluency)

Inclusion Criteria for Caregiver are:

  • Age 18 or Older
  • Moderate to good English fluency (self-rated English fluency)
  • Willing to participate in intervention with PLWD

Exclusion criteria

Exclusion criteria for PLWD are:

  • Medical diagnosis of severe dementia (any etiology)
  • Non-AD dementia diagnosis (e.g., frontotemporal dementia)
  • Serious medical condition (e.g., an end-stage disease requiring hospice, aphasia from stroke, paralysis, brain injury) requiring active medical management that would interfere with participation in the study
  • Significant difficulty moving the hands or arms (severe arthritis, neuropathy)
  • Plans to move out of the area within six months

Exclusion criteria for Caregiver are:

  • Current but not prior severe psychiatric disorder (e.g., schizophrenia, bipolar disorder)
  • Serious medical condition (e.g., an end-stage disease requiring hospice, aphasia from stroke, paralysis, brain injury) requiring active medical management that would interfere with participation in the study
  • Plans to move out of the area

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • University of California, San Francisco — San Francisco

Identifiers

NCT: NCT07419022 · 5K01AG088475-02 · 1K01AG088475-01A1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗